ALPINE: Zanubrutinib or Ibrutinib in Relapsed/Refractory CLL

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell lymphoma.

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma.